natalizumab biosimilar (R-Pharm)

N/A

Report date: 2025/01/26 19:10:42

Base Information

Drug Namenatalizumab biosimilar (R-Pharm)
Drug Alias NameTysabri biosimilar (R-Pharm)RPH-017
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionIntegrin alpha-4/beta-1 antagonists
TargetsIntegrin alpha-4/beta-1
Therapy Area/IndicationsMultiple Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryRussian Federation
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesR-Pharm Jsc
China Registration ClassN/A

Develop Information

Active CompaniesR-Pharm Jsc
Inactive CompaniesN/A
Active IndicationsMultiple Sclerosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A